NanJing Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
NanJing Pharmaceutical has been growing earnings at an average annual rate of 15.7%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 10.3% per year. NanJing Pharmaceutical's return on equity is 9.7%, and it has net margins of 1.1%.
Key information
15.7%
Earnings growth rate
10.3%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 10.3% |
| Return on equity | 9.7% |
| Net Margin | 1.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NanJing Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 53,460 | 588 | 1,682 | 38 |
| 31 Dec 23 | 53,590 | 578 | 1,674 | 36 |
| 30 Sep 23 | 53,332 | 566 | 1,740 | 34 |
| 30 Jun 23 | 53,624 | 571 | 1,734 | 32 |
| 31 Mar 23 | 52,603 | 612 | 1,741 | 31 |
| 31 Dec 22 | 50,222 | 596 | 1,720 | 27 |
| 30 Sep 22 | 49,163 | 629 | 1,625 | 26 |
| 30 Jun 22 | 47,167 | 616 | 1,586 | 24 |
| 31 Mar 22 | 45,739 | 536 | 1,547 | 21 |
| 31 Dec 21 | 45,123 | 505 | 1,520 | 21 |
| 30 Sep 21 | 44,140 | 440 | 1,457 | 22 |
| 30 Jun 21 | 43,442 | 426 | 1,464 | 18 |
| 31 Mar 21 | 42,113 | 402 | 1,455 | 16 |
| 31 Dec 20 | 39,817 | 376 | 1,403 | 16 |
| 30 Sep 20 | 38,538 | 335 | 1,425 | 14 |
| 30 Jun 20 | 37,514 | 360 | 1,381 | 15 |
| 31 Mar 20 | 37,209 | 351 | 1,364 | 16 |
| 31 Dec 19 | 37,156 | 347 | 1,370 | 13 |
| 30 Sep 19 | 35,745 | 360 | 1,370 | 13 |
| 30 Jun 19 | 34,062 | 285 | 1,299 | 12 |
| 31 Mar 19 | 32,282 | 272 | 1,244 | 12 |
| 31 Dec 18 | 31,303 | 264 | 1,200 | 11 |
| 30 Sep 18 | 31,608 | 258 | 1,281 | 8 |
| 30 Jun 18 | 30,473 | 259 | 1,227 | 6 |
| 31 Mar 18 | 29,884 | 237 | 1,217 | 2 |
| 31 Dec 17 | 28,810 | 232 | 1,167 | 2 |
| 30 Sep 17 | 27,452 | 225 | 976 | 1 |
| 30 Jun 17 | 27,253 | 211 | 963 | 1 |
| 31 Mar 17 | 26,831 | 191 | 959 | 0 |
| 31 Dec 16 | 26,721 | 180 | 955 | 0 |
| 30 Sep 16 | 26,157 | 164 | 986 | 0 |
| 30 Jun 16 | 25,786 | 158 | 964 | 0 |
| 31 Mar 16 | 25,490 | 158 | 937 | 0 |
| 31 Dec 15 | 24,813 | 157 | 928 | 0 |
| 30 Sep 15 | 24,009 | 199 | 888 | 0 |
| 30 Jun 15 | 23,327 | 184 | 900 | 0 |
| 31 Mar 15 | 22,719 | 167 | 891 | 0 |
| 31 Dec 14 | 22,076 | 129 | 885 | 0 |
| 30 Sep 14 | 21,311 | 65 | 839 | 0 |
| 30 Jun 14 | 20,505 | 46 | 861 | 0 |
| 31 Mar 14 | 19,828 | 44 | 828 | 0 |
| 31 Dec 13 | 19,236 | 39 | 849 | 0 |
| 30 Sep 13 | 18,655 | 34 | 929 | 0 |
| 30 Jun 13 | 18,424 | 81 | 965 | 0 |
Quality Earnings: 600713 has high quality earnings.
Growing Profit Margin: 600713's current net profit margins (1.1%) are lower than last year (1.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600713's earnings have grown by 15.7% per year over the past 5 years.
Accelerating Growth: 600713's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600713 had negative earnings growth (-4%) over the past year, making it difficult to compare to the Healthcare industry average (-1%).
Return on Equity
High ROE: 600713's Return on Equity (9.7%) is considered low.